2014 Antibody Engineering Symposium Speaker Bios

Aaron K. Sato, Ph.D.

Vice President of Research, Sutro Biopharma

Dr. Sato has more than 10 years of industrial research experience in antibody, protein and peptide engineering. At Sutro, Aaron is Vice President of Research and leads the team in the use of their bacterial extract system to produce high value protein therapeutics, such as ADC, bispecifics, and naked antibodies. Prior to joining Sutro, he was senior director of antibody engineering at OncoMed Pharmaceuticals, where his team discovered several antibodies for its clinical pipeline. Before this, he held director positions at Dyax Corp., where he oversaw multiple external collaborations with major pharmaceutical companies. Dr. Sato holds many patents and is the author of numerous peer-reviewed publications. He received a doctorate in chemistry from Massachusetts Institute of Technology and a bachelor's degree in chemistry from the University of Puget Sound.

Jaume Pons, Ph.D.

CSO/SVP, Rinat/Pfizer

Jaume Pons, Ph.D., is Senior Vice President and Chief Scientific Officer of Rinat, the biotech unit of Pfizer in South San Francisco, California. In this role, he is responsible for portfolio delivery from idea to clinical development, up to human proof of concept. Dr. Pons also serves as Chief Technology Officer, focused on antibody technologies, and is a member of the Pfizer Worldwide Research and Development leadership team. Previously, Dr. Pons created and led Rinat’s protein engineering group, and is an inventor of several antibodies that are now in late-stage clinical development, including RN624 (tanezumab) and RN316 (bococizumab). Under his direction, Rinat continues to advance Pfizer’s growing capabilities in generating therapeutic antibodies, and has progressed eight antibodies into the clinic. Dr. Pons earned his Ph.D. in molecular and cell biology at the Institute on Fundamental Biology, Barcelona, Spain, and his B.S. in biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.

Michael J. Hornsby, Ph.D.

Researcher Professional, The University of California, San Francisco (UCSF)

Dr. Hornsby is the Project Manager for the UCSF Antibiome Center and the Recombinant Antibody Network (RAN). He has over 15 years of research experience focusing on protein biochemistry, antibody engineering, microbial pathogenesis, laboratory automation, and process development. Since joining the RAN he has focused on the development of high-throughput pipelines used to generate and validate recombinant antibodies utilizing phage-display and automated protein expression pipelines used to supply the antibody discovery pipeline. These technologies are being employed to generate renewable open source recombinant antibodies for the proteome.

Ryan Stafford, Ph.D.

Group Leader, Protein Engineering, Sutro Biopharma

Dr. Stafford currently leads the Protein Engineering Discovery group at Sutro Biopharma, Inc. in South San Francisco. His team combines ribosome and phage display with rational approaches to antibody discovery and optimization for Sutro's proprietary cell-free protein synthesis platform, XpressCF. Previously, Ryan earned his Ph.D. with Professor Peter Dervan at Caltech on the design of small-molecule protein-DNA dimerizers. He also completed a postdoctoral fellowship with Professor James Bowie at UCLA where he used protein crystallography and other methods to study several brain-specific proteins.

Cheng Liu, Ph.D.

CEO and Founder, Eureka Therapeutics

Dr. Liu is the founder and CEO of Eureka Therapeutics, Inc. Prior to founding Eureka, Dr. Liu served as a principal scientist in the Antibody Drug Discovery program at Chiron (now part of Novartis). Dr. Liu has over 20 years of experience in biology research and drug discovery with extensive experience and knowledge in cancer therapeutic antibody discovery and development, including target identification, validation, assay development, and screening for drug candidates. He is the inventor of 18 patents filed in the US and Europe. He also served as president of SAPA-West from 2004-2005 and on its Executive and Advisory committees from 1998-2007. Dr. Liu received his B.S. in Genetics from Beijing University, M.S. in Molecular Biology from Beijing University, and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.

William Robinson, M.D., Ph.D.

Associate Professor, Stanford University

Dr. Robinson co-founded Atreca and is currently Associate Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University, Staff Physician at the Veterans Affairs Palo Alto Health Care System, and Director of the Stanford Osteoarthritis Initiative. He and his laboratory members invented the technology underlying Atreca's Immune Repertoire Capture™ technology. The major objective of Dr. Robinson's laboratory is translational bench-to-bedside research, with the goal of rapidly converting discoveries at the bench into practical patient care tools and therapies. He is an inventor on nineteen patent applications, and technologies developed in his Stanford and VA laboratories have been licensed to seven companies in the biotechnology industry. Dr. Robinson was a co-founder of Bayhill Therapeutics. He also founded the Stanford Human Immune Monitoring Center, serves on the editorial boards of several major journals, and is an elected member of the American Society of Clinical Investigation. Dr. Robinson received his BS, MD, and PhD degrees from Stanford University and completed his clinical training in internal medicine at the University of California, San Francisco.

Jennifer Cochran, Ph.D.

Associate Professor, Stanford University

Jennifer Cochran is an associate professor of bioengineering, and has a secondary appointment in chemical engineering. Her research group uses interdisciplinary approaches in chemistry, engineering, and biophysics to study complex biological systems and develop new technologies for basic science and biomedical applications. Professor Cochran's research is driven by the philosophy that in order to effectively control physiological processes it is necessary to understand the molecular mechanisms that drive these processes. Her group is interested in elucidating molecular details of receptor-mediated cell signaling events; at the same time developing protein and peptide-based tools that will allow manipulation of cellular processes on a molecular level. For biomedical applications, rational design and combinatorial methods are used to create designer protein therapeutics and diagnostic agents for applications such as regenerative medicine and cancer imaging and therapy.

Roland Buelow, Ph.D.

CEO, OMT, Inc.

Dr. Buelow has worked in biotechnology for 28 years and has extensive pharmaceutical experience. He was a founder of Therapeutic Human Polyclonals, Inc. (THP), a biotechnology company that engineered rabbits to produce human antibodies and was acquired by Roche in 2007. Between 1993 and 2003, Dr. Buelow was SVP of Research and Development at SangStat Medical Corporation (SMC), where he led antibody and

other immunology research product development, including a clinically successful anti-inflammatory compound, RDP58. Dr. Buelow has published more than 100 manuscripts and is an inventor on more than 25 patents.

David Meininger, Ph.D., M.B.A.

Executive Director, Molecular Discovery, Merck

Dr. Meininger joined Merck in 2011 as Head of Protein Sciences. He served as a member of the Biologics Review & Licensing Committee, as champion of the Adimab collaboration, as co-champion of the Ambrx antibody-drug conjugate collaboration and played a strategic role on other Merck partnerships. In 2013, Dr. Meininger joined the new Merck Research Labs Business Development & Licensing organization. His BD&L responsibilities include scouting and evaluation of licensing opportunities in immuno-oncology and involving biologic assets from pre-clinical through clinical POC, support of the Merck Research Ventures Fund team and other BD activities.

Prior to joining Merck, Dr. Meininger held positions with Amgen, Boehringer Ingelheim, Genentech, and Tularik. Dr. Meininger holds a Ph.D. in Chemistry from the University of California, San Diego, a M.B.A. in Technology Management from the University of Washington and a B.S. in Chemistry from the University of Florida.

Simon Jackson, Ph.D.

Scientific Director, Amgen

Dr. Jackson received his Ph.D. in Biochemistry from the University of Manchester, UK, in 1986, completed postdoctoral training at UCLA and served as Adjunct Assistant Professor at the same institution from 1996 to 2000. Simon joined the Tularik Biology group in South San Francisco in 2000 working on small molecule inhibitors of DGAT1. He subsequently became part of the Metabolic Disorders group of Amgen Inc in 2004 following the Tularik acquisition. At Amgen Simon has worked on the biology of PCSK9 and the antibody program for inhibiting PCSK9.

Austin Gurney, Ph.D.

SVP, Molecular and Cellular Biology, OncoMed Pharmaceuticals

Austin Gurney joined OncoMed Pharmaceuticals at its founding as Vice President of Molecular and Cellular Biology. Prior to OncoMed, Dr. Gurney worked at Genentech

where his research contributed to the discovery of numerous growth factors and cytokines. He has authored or co-authored more than 60 papers and is listed as an inventor on over 600 patents related to therapeutic applications in immunology and cancer. Dr. Gurney has two decades of experience in biotechnology and in the development of novel therapeutics. Dr. Gurney conducted his Ph.D. work at Case Western Reserve University. He completed post-doctoral studies with Dr. Bryan Williams at the Cleveland Clinic, and at Genentech with Dr. David Goeddel.

Germaine Fuh

Senior Scientist, Genentech

Dr. Fuh is a senior scientist in the Antibody Engineering Department at Genentech focusing on the technology of combinatorial antibody libraries for novel antibody discovery for human disease intervention. She recently developed a strategy to engineer antibodies to target two different molecules at the antigen-binding site, which has been useful as an option for generating therapeutic antibody.

Nuno Fontes, Ph.D.

Director of Protein Science, Boehringer Ingelheim

Dr. Fontes is the Director of Protein Science at Boehringer Ingelheim, in Fremont California. Before joining Boehringer Ingelheim, Nuno worked at Genentech (Roche Group) in South San Francisco (California) for 9 years, where he was a Senior Engineer and Group Leader in the Pharmaceutical Technical Development department. Nuno has 13 years of industrial bioprocess and technology development leadership experience. He has led multiple projects and cross-functional teams in a wide range of areas including technical development (CMC team leadership), early and late stage purification process development, process characterization and validation, process transfer and implementation at clinical and commercial scale, new technology development collaborations, process and facility fit modeling, process economics, among others. Before joining Genentech in 2004, he had started his industrial career in 2000 as a Senior Scientist and Group Leader at Biotecnol SA in Portugal. Nuno received a Ph.D. in Chemical Engineering from ITQB-UNL in Portugal in collaboration with the University of Strathclyde in Scotland, an MS in biotechnology and a BS in Applied Chemistry from FCT-UNL, in Portugal. He has a postgraduation in Commercialization of Science and Technology from the Technical University of Lisbon in collaboration with the University of Texas at Austin, a post graduation in Project Management from the Autonomous University of Lisbon and a Project Management Professional (PMP) certification from the Project Management Institute. He has co-chaired several sessions at scientific conferences, presented at many national and international meetings, and co-authored 8 journal articles and 3 book chapters.

Fan Chen, Ph.D.

Director of Bioprocessing, LakePharma

Dr. Chen is the Director of Bioprocessing at LakePharma, Inc. He received a B.S. degree in Chemical Engineering from Tsinghua University, and a Ph.D. in Biochemical Engineering from the University of Akron. He has nearly 20 years of bioprocessing development experience with proteins, viruses, lipids, and other metabolites production at different scales. Prior to joining LakePharma, Fan was a senior scientist and group leader of upstream cell culture process development at Dendreon, focused on second generation commercial protein production development. Prior to Dendreon, Fan was a cell culture processing development scientist at MedImmune/AstraZeneca, where he developed several cell culture processes to support multiple Phase I and Phase II clinical trial material manufacturing.

Michael P. Gillmeister, Ph.D.

Senior Scientist, R&D, Thermo Fisher Scientific

Dr. Gillmeister received his Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University in collaboration with the University of Maryland School of Medicine where he specialized in glycosylation, transient protein production, and neurobiology. In 2009, Mike joined the Gibco research and development group of Life Technologies™ (then Invitrogen™) and was responsible for next-generation media and sera projects. He then joined the PD-Direct Media Services team and led media and process development projects using high-throughput and bioreactor technologies. Currently, Mike focuses on techniques to modulate product quality and maximize titer through process development with the Gibco applications team.

Jason Schuman, Ph.D.

Senior Biacore Application Scientist, GE Life Sciences

Dr. Schuman was introduced to biophysical chemistry during his Ph.D. at the University of Washington. There he studied the humoral immune systems recognition of peptide-based breast cancer vaccine. That class of molecules (MUC-1) is still being investigated as a cancer therapeutic. He continued studies of biomolecular interactions during his postdoctoral fellowship with Richard Brennan at Oregon Health Science University. There he studied transcriptional regulation of bacterial multidrug resistance by analyzing antibiotic binding using a structural and biophysical approach. Dr. Schuman has been at Biacore (now GE Healthcare) for over 8 years. He has been involved with product development, training and several publications in the field of HIV vaccine development,

development of improved Factor VIII therapeutics and more recently, CRISPR research. He has a passion for the application of biophysical approaches to the study of diseases and the development of therapeutics.